Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy~* HbA1c ≥7.0% and ≤10.0% before study start~Exclusion Criteria:~* History of Type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation and sodium glucose cotransporter 2 (SGLT2) inhibitors anytime~* Currently has a urinary tract infection or genital infection with subjective symptom

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipragliflozin + Sitagliptin (Type: EXPERIMENTAL): Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
- Placebo + Sitagliptin (Type: ACTIVE_COMPARATOR): Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).